Updates are available Correction dated 2023-07-03

Article History

Received: 29 March 2022

Accepted: 21 November 2022

First Online: 23 February 2023

Change Date: 3 July 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41591-023-02473-7

Competing interests

: The clinical trial was supported by Agios Pharmaceuticals, Inc. Servier Pharmaceuticals LLC completed the acquisition of Agios’ oncology business. I.K.M. reports serving as a consultant for Agios Pharmaceuticals, Black Diamond Therapeutics, Debiopharm Group, Puma Biotechnology, Servier Pharmaceuticals LLC, Voyager Therapeutics, DC Europa Ltd, Kazia Therapeutics, Novartis, Cardinal Health, Roche, Vigeo Therapeutics and Samus Therapeutics. M.L. reports employment with and stock ownership at Agios Pharmaceuticals Inc. and employment with Servier Pharmaceuticals LLC during the conduct of the study. P.Y.W. reports research support from AstraZeneca/MedImmune, Beigene, Celgene, Chimerix, Eli Lily, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Servier Pharmaceuticals LLC, Vascular Biogenics and VBI Vaccines; and serving on an advisory board for AstraZeneca, Bayer, Black Diamond, Boehringer Ingelheim, Boston Pharmaceuticals, Celularity, Chimerix, Day One Bio, Genenta, GlaxoSmithKline, Karyopharm, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier Pharmaceuticals LLC, Sagimet, Vascular Biogenics and VBI Vaccines. J.W.T. reports involvement as a principal investigator and involved in data collection and analysis, and manuscript preparation for clinical trials with BMS, Navio and AbbVie within the last five years. K.B.P. reports research support from Servier Pharmaceuticals LLC. B.M.E. reports serving as a consultant for MedQIA and Servier Pharmaceuticals LLC. K.L. reports employment with and stock ownership at Agios Pharmaceuticals Inc. during the conduct of the study. A.T. reports employment with and stock ownership at Agios Pharmaceuticals Inc. and employment with Servier Pharmaceuticals LLC. S. Choe reports employment with and stock ownership at Agios Pharmaceuticals Inc. and employment with Servier Pharmaceuticals LLC. Y.T. reports employment with and stock ownership at Agios Pharmaceuticals Inc. and employment with Servier Pharmaceuticals LLC during the conduct of the study. S.S. reports employment with and stock ownership at Agios Pharmaceuticals Inc. and employment with Servier Pharmaceuticals LLC. S.S.P. reports employment with and stock ownership at Agios Pharmaceuticals Inc. and employment with Servier Pharmaceuticals LLC. I.H. reports employment with and stock ownership at Agios Pharmaceuticals Inc. and employment with Servier Pharmaceuticals LLC. L.S. reports employment with and stock ownership at Agios Pharmaceuticals Inc. and employment with Servier Pharmaceuticals LLC. J.L.C. reports serving as a consultant for Agios Pharmaceuticals Inc. and Servier Pharmaceuticals LLC. T.F.C. reports being a cofounder, major stock holder, consultant and board member of Katmai Pharmaceuticals, and membership of the board, and paid consultancy for the 501c3 Global Coalition for Adaptive Research; holding stock in Chimerix and receiving milestone payments and possible future royalties; membership of the scientific advisory boards for Break Through Cancer and Cure Brain Cancer Foundation; providing paid consulting services to Sagimet, Clinical Care Options, Ideology Health, Servier, Jubilant, Immvira, Gan & Lee, BrainStorm, Katmai, Sapience, Inovio, Vigeo Therapeutics, DNATrix, Tyme, SDP, Novartis, Roche, Kintara, Bayer, Merck, Boehringer Ingelheim, VBL, Amgen, Kiyatec, Odonate Therapeutics QED, Medefield, Pascal Biosciences, Bayer, Tocagen, Karyopharm, GW Pharma, Abbvie, VBI, Deciphera, VBL, Agios, Genocea, Celgene, Puma, Lilly, BMS, Cortice, Wellcome Trust, Novocure, Novogen, Boston Biomedical, Sunovion, Human Longevity, Insys, ProNai, Pfizer, Notable labs, Medqia Trizel, Medscape; contracts with UCLA for the Brain Tumor Program with Oncovir, Merck, Oncoceutics, Novartis, Amgen, Abbvie, DNAtrix, Beigene, BMS, AstraZeneca, Kazia, Agios, Boston Biomedical, Deciphera, Tocagen, Orbus, AstraZeneca, Karyopharm; and the Regents of the University of California (T.F.C.’s employer) have licensed intellectual property co-invented by T.F.C. to Katmai Pharmaceuticals. No disclosures were reported by the other authors.